The influence of glucose abnormalities on the efficacy of antiviral treatment is unknown.
Dr Albert Lecube and colleagues from Spain investigated whether glucose abnormalities influence the response to antiviral therapy with interferon plus ribavirin in patients with chronic Hepatitis C.
The team retrospectively assessed a total of 178 patients with chronic Hepatitis C treated with combination therapy.
|The sustained virological response rate was 28% with impaired fasting glucose|
|The American Journal of Gastroenterology|
Sustained virological response was assessed after completing treatment.
Fasting plasmatic glucose was measured prior to therapy.
The team compared 111 no responders with 67 patients with sustained virological response.
Non responders had lower plasma glucose, and a lower prevalence of glucose abnormalities.
The sustained virological response rate was 45% in patients with normoglycemia, and 28% in patients with impaired fasting glucose, and 16% in type 2 diabetic patients.
The researchers observed that genotype 1, and gamma-glutamyltranspeptidase levels were independently associated with the absence of an sustained virological response.
The team noted that the presence of glucose abnormalities were independently associated with the absence of an sustained virological response.
Patients with glucose abnormalities showed a lower virological response rate when compared with a subgroup of normoglycemic patients.
The researchers reported that the patients were matched for sex, age, and liver fibrosis.
Dr Lecube's team concluded, " Glucose abnormalities are an independent predictor of poor virological response to combined therapy in hepatitis C virus infected patients."